StockData

BioMarin Pharmaceutical vs Royalty Pharma

BMRN and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BMRN and RPRX compare

Royalty Pharma is the larger company, worth 3.5 times as much as BioMarin Pharmaceutical ($39.5B against $11.3B).

On earnings, Royalty Pharma is cheaper: it trades at 39.0× trailing earnings, against 154× for BioMarin Pharmaceutical.

BioMarin Pharmaceutical grew revenue faster over the last twelve months (11.2% versus 10.0% for Royalty Pharma).

Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with 2.1% at BioMarin Pharmaceutical.

Royalty Pharma pays a dividend yielding 1.4%; BioMarin Pharmaceutical does not pay one.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBMRNRPRX
Size and price
Market cap$11.3B$39.5B
Share price$58.51$68.68
Change, 1 year6.9%75.4%
Change, 5 years−33.2%64.0%
Beta (5Y)0.380.04
Employees3,221100
StockData Score
Total score88
Valuation score1 (better)0
Growth score3 (better)2
Performance score22
Health score22
Dividend score02 (better)
Valuation
P/E154×39.0× (better)
P/S3.3× (better)15.6×
P/B1.8×–
EV/EBITDA48.4×33.5× (better)
P/FCF15.3×–
PEG4.540.24 (better)
FCF yield6.5%–
Fair value$30.34$45.76
Margin of safety−92.9%−50.1% (better)
Growth
Revenue growth (TTM)11.2% (better)10.0%
Revenue growth, 5Y average11.6% (better)2.3%
Net income growth (TTM)−88.9%−20.4% (better)
EPS growth (TTM)−88.7%−19.3% (better)
EPS growth, 5Y average−16.7%6.2% (better)
Profitability
Gross margin76.1%–
Operating margin4.4%59.6% (better)
Net margin2.1%32.1% (better)
FCF margin21.7%–
Return on equity1.2%–
Return on invested capital1.0%–
Financial health
Debt / equity0.66–
Net debt / EBITDA10.965.37 (better)
Interest coverage2.0×4.2× (better)
Current ratio2.392.80 (better)
Altman Z-score1.862.98 (better)
Piotroski F-score45 (better)
Dividends and buybacks
Dividend yield–1.4%
Buyback yield–0.81%
Shareholder yield0.00%2.2% (better)
Ownership
Held by institutions101%63.8%
Held by insiders0.52%22.6%
Insider net buying, 12 months−$4.3M (better)−$82.2M
Superinvestors holding12 (better)
Short interest, % of float7.3%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.